Summary
Cipla has received U.S. FDA approval for a generic version of an asthma and COPD drug, marking its first dry powder inhaler approval from its U.S.-based manufacturing network, with a launch expected in Q2 FY27.
Cipla Gets U.S. FDA Approval for Generic Asthma, COPD Drug
HyperFast News
Related news
Maharashtra FDA withdraws Cipla Pharma license cancellation order after Bombay HC criticism
18 Sept 2026, 7:44 pm · News
Maharashtra FDA Cancels Cipla Unit's Drug Licence for Reactin Plus Irregularities
18 Sept 2026, 7:44 pm · News
Cipla Expects US Sales Ramp-Up by FY27, Maintains Full-Year Guidance
18 Sept 2026, 7:44 pm · News
